EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rising Prevalence of Central Nervous System Involvement in Multiple Myeloma: A 2012-2020 National Inpatient Sample (NIS) Analysis in the United States

Charles J Mazof, Vishva Natarajan, Augustos Vrattos, Parth Shah, Frederick Lansigan, Jennifer Hong

Clinical Lymphoma Myeloma and Leukemia · 2025

DOI: 10.1016/j.clml.2025.12.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Charles J Mazof und 5 weiteren Autor:innen. Beteiligte Einrichtung: Geisel School of Medicine at Dartmouth, Hanover, NH. Hauptthemen laut MEDLINE: Multiple Myeloma, Central Nervous System Neoplasms. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Central nervous system involvement in multiple myeloma (CNS-MM) is a rare but aggressive extramedullary manifestation occurring in approximately 1% of multiple myeloma (MM) patients. CNS-MM is associated with poor prognosis, with median survival ranging from 2 to 7 months. Small studies have suggested that advances in MM treatment may be leading to increasing prevalence of CNS-MM; however, a comprehensive analysis of temporal trends is lacking. METHODS: We conducted an epidemiological study of the 2012-2020 National Inpatient Sample, an all-payer database of US inpatient hospital admissions. Patients aged 18 and older with both MM and secondary CNS neoplasms were identified using ICD-9 and ICD-10 diagnosis codes. We then calculated weighted prevalence estimates and assessed them using regression analysis. RESULTS: CNS-MM prevalence increased significantly, increasing by 166% from 2012 to 2020 (P < .001). This increase outpaced the 29% rise in overall MM prevalence (P < .001) during the same period. We observed no significant changes in mortality or discharge outcomes over time. Patients who were white (P < .05) and had income over median (P < .01) received more CNS-targeting diagnostic or therapeutic care, but we found no evidence of improved inpatient survival due to these procedures (P = .70) after adjusting for disease severity. CONCLUSION: The prevalence of CNS-MM has grown to 2%-3% of MM patients since 2020, with stable rates of mortality despite interventions. Further investigation is needed to explore underlying mechanisms of this growth and improve outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaCentral Nervous System NeoplasmsHumansFemaleMaleUnited StatesPrevalenceMiddle AgedAgedInpatientsAdultAged, 80 and overYoung AdultHospitalization

Stichwörter der Autor:innen

Blood-brain barrierCancer relapseEpidemiological trendsExtramedullary diseaseSocioeconomic disparities

Autor:innen und Institutionen

  • Geisel School of Medicine at Dartmouth, Hanover, NH.
  • Department of Medicine, Hematology Oncology Section, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
  • Geisel School of Medicine at Dartmouth, Hanover, NH; Department of Surgery, Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH. Electronic address: jennifer.hong@hitchcock.org.

Zitieren

APA

Mazof, C. J., Natarajan, V., Vrattos, A., Shah, P., Lansigan, F., & Hong, J. (2025). Rising Prevalence of Central Nervous System Involvement in Multiple Myeloma: A 2012-2020 National Inpatient Sample (NIS) Analysis in the United States. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.12.004

Vancouver

Mazof CJ, Natarajan V, Vrattos A, Shah P, Lansigan F, Hong J. Rising Prevalence of Central Nervous System Involvement in Multiple Myeloma: A 2012-2020 National Inpatient Sample (NIS) Analysis in the United States. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2025.12.004

BibTeX
@article{Mazof2025,
  author = {Mazof, Charles J and Natarajan, Vishva and Vrattos, Augustos and Shah, Parth and Lansigan, Frederick and Hong, Jennifer},
  title = {Rising Prevalence of Central Nervous System Involvement in Multiple Myeloma: A 2012-2020 National Inpatient Sample (NIS) Analysis in the United States},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2025},
  doi = {10.1016/j.clml.2025.12.004}
}
Kostenlos starten →